This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|October 24, 2014
Janssen Pulls 13,500 Bottles of Xarelto, Cites Contamination
Author(s)Randi Hernandez
A customer complaint prompts the recall of a lot of anticoagulants from a plant in Puerto Rico.
Advertisement
Janssen announced in mid-October that it is recalling 13,500 bottles of Xarelto (rivaroxaban) after a customer complained about a microbial contaminant in a sales sample. Xarelto is used to reduce the risk of stroke and blood clots in people with atrial fibrillation.
The lots of the medication were traced to a facility in Gurabo, Puerto Rico, according to a recall notice in the latest FDA Enforcement Report. The recall action was voluntary, and the whole lot was recalled based on contaminants reported in only one bottle. The sales sample sizes that were pulled contained only five 15 mg pills in each bottle. Janssen said in a statement all Xarelto dosage strengths remain available for patients and product obtained at a pharmacy is not impacted.
Sources:
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement